scholarly journals Ongoing Use of Data and Specimens From National Cancer Institute–Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program

2015 ◽  
Vol 42 (5) ◽  
pp. 748-763 ◽  
Author(s):  
Lori M. Minasian ◽  
Catherine M. Tangen ◽  
D. Lawrence Wickerham
Keyword(s):  
Clinical Trials ◽  
Cancer Prevention ◽  
Clinical Oncology ◽  
National Cancer Institute ◽  
Use Of Data ◽  
Community Clinical Oncology Program

Quality-of-Life Assessment in the Symptom Management Trials of the National Cancer Institute-Supported Community Clinical Oncology Program

2005 ◽  
Vol 23 (3) ◽  
pp. 591-598 ◽  
Author(s):  
David R. Buchanan ◽  
Ann M. O'Mara ◽  
Joseph W. Kelaghan ◽  
Lori M. Minasian
Keyword(s):  
Quality Of Life ◽  
Clinical Trials ◽  
Clinical Oncology ◽  
National Cancer Institute ◽  
Symptom Management ◽  
Symptom Relief ◽  
Life Assessment ◽  
Specific Symptom ◽  
Community Clinical Oncology Program

Purpose To examine how quality of life (QOL) is prospectively conceptualized, defined, and measured in the symptom management clinical trials supported by the National Cancer Institute Community Clinical Oncology Program (CCOP). Methods All QOL research objectives, rationales, assessment instruments, symptoms treated, and types of interventions from the CCOP symptom management portfolio of clinical trials were extracted and analyzed. Results QOL assessments were proposed in 68 (52%) of the 130 total CCOP symptom management trials initiated since 1987. A total of 22 global QOL instruments were identified. Both the frequency of symptom management trials and the frequency of QOL assessment have increased significantly over time. The Functional Assessment of Cancer Therapy and Uniscale instruments were the most widely used QOL instruments, included in 55% of trials assessing QOL. The conceptual framework for QOL inclusion was limited to univariate relationships between symptom relief and global improvements in QOL. No consistent associations were found between QOL assessment and either the symptoms targeted or types of interventions. Conclusion To advance the state of the science, research protocols need to provide more explicit rationales for assessing QOL in symptom management trials and for the selection of the QOL instrument(s) to be used. Conceptual frameworks that specify the hypothesized links between the specific symptom(s) being managed, interactions with other symptoms, different domains of QOL, and global QOL also need to be more precisely described. Methodologic and conceptual advances in QOL symptom management trials are critical to fulfill the promise of alleviating suffering and improving the QOL of cancer patients.

A prospective study of patient accrual to clinical trials at a NCI-funded Community Clinical Oncology Program

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 9610-9610 ◽  
Author(s):  
G. S. Soori ◽  
M. B. Wilwerding ◽  
M. Carlson ◽  
J. Verdirame ◽  
P. Townley ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Prospective Study ◽  
Clinical Oncology ◽  
Community Clinical Oncology Program ◽  
A Prospective Study ◽  
Patient Accrual

Reforming the Community Research Program: From Community Clinical Oncology Program to the National Cancer Institute Community Oncology Research Program

2014 ◽  
pp. e116-e119 ◽  
Author(s):  
Robin T. Zon
Keyword(s):  
Clinical Oncology ◽  
Research Program ◽  
Community Involvement ◽  
National Cancer Institute ◽  
Care Delivery ◽  
Community Research ◽  
Community Clinical Oncology Program ◽  
Oncology Research ◽  
Community Oncology ◽  
Control Research

Community research has been an integral and influential component of the National Research Program since the late 1970s. Institutionalization of community research in the Community Clinical Oncology Program (CCOP) has resulted in successful collaborations, meaningful accrual, achievement of quality standards, and translation of research into clinical practice. Although the national clinical trial system is undergoing modernization and improvement, the success of the CCOP and minority-based CCOP in cancer treatment, prevention, and control research is being extended to include cancer care delivery research in the newly created National Cancer Institute (NCI) Community Oncology Research Program. This article briefly presents a historic perspective of community involvement in federally sponsored clinical trials and introduces the continued involvement in the newly created NCI program.

scholarly journals Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program

2016 ◽  
Vol 12 (4) ◽  
pp. e388-e395 ◽  
Author(s):  
Michael E. Roth ◽  
Ann M. O’Mara ◽  
Nita L. Seibel ◽  
David S. Dickens ◽  
Anne-Marie Langevin ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Young Adults ◽  
Clinical Oncology ◽  
Community Setting ◽  
Cancer Control ◽  
Adolescents And Young Adults ◽  
Trial Participation ◽  
Targeted Interventions ◽  
Community Clinical Oncology Program ◽  
Oncology Research

Purpose: Stagnant outcomes for adolescents and young adults (AYAs; 15 to 39 years old) with cancer are partly attributed to poor enrollment onto clinical trials. The National Cancer Institute (NCI) Community Clinical Oncology Program (CCOP) was developed to improve clinical trial participation in the community setting, where AYAs are most often treated. Further, many CCOP sites had pediatric and medical oncologists with collaborative potential for AYA recruitment and care. For these reasons, we hypothesized that CCOP sites enrolled proportionately more AYAs than non-CCOP sites onto Children’s Oncology Group (COG) trials. Methods: For the 10-year period 2004 through 2013, the NCI Division of Cancer Prevention database was queried to evaluate enrollments into relevant COG studies. The proportional enrollment of AYAs at CCOP and non-CCOP sites was compared and the change in AYA enrollment patterns assessed. All sites were COG member institutions. Results: Although CCOP sites enrolled a higher proportion of patients in cancer control studies than non-CCOP sites (3.5% v 1.8%; P < .001), they enrolled a lower proportion of AYAs (24.1% v 28.2%, respectively; P < .001). Proportional AYA enrollment at CCOP sites decreased during the intervals 2004 through 2008 and 2009 through 2013 (26.7% v 21.7%; P < .001). Conclusion: Despite oncology practice settings that might be expected to achieve otherwise, CCOP sites did not enroll a larger proportion of AYAs in clinical trials than traditional COG institutions. Our findings suggest that the CCOP (now the NCI Community Oncology Research Program) can be leveraged for developing targeted interventions for overcoming AYA enrollment barriers.

Sign in / Sign up

Export Citation Format

Share Document